PORTON

Enabling the Public’ s Early Access to Good Medicines

NEWSLETTER

June 2025

Porton Pharma Solutions Ltd.

Contents

Technical Enabling

Multiple Approaches to Address the Challenges of Oral Absorption of PROTAC Drugs

2025-06-27

As a global CDMO serving innovative pharmaceutical companies and research institutions, Porton has extensive experience in research and manufacturing services, especially in the field of PROTAC drug development. Porton is committed to the development and production of PROTAC oral formulations and provides customers with comprehensive, reliable, fast, and compliant one-stop services, supporting supply chain needs and enabling the commercial success of products from research and development through to order fulfillment.

CASE STUDIES PORTON

Introduction

A proteolysis targeting chimera (PROTAC) is a heterobifunctional molecule consisting of two covalently linked protein-binding domains: a target protein ligand and an E3 ubiquitin ligase ligand. After binding to the target protein, E3 ligase is first recruited for ubiquitination to form a stable ternary complex, and the target protein is then degraded by proteasome mediation. PROTACs put the protein of interest in close proximity to the E3 ligase to catalyze degradation. PROTACs have a catalytic mechanism, with the PROTAC itself being recycled after the target protein is degraded. Due to their catalytic mechanism, PROTACs can be administered at lower doses. As PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzyme activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

In recent years, PROTAC technology has been popular in the field of oncology drug development, and researchers have used this technology to develop a large number of PROTACs targeting oncoproteins. PROTAC technology is designed to induce the degradation of proteins, not to inhibit them like traditional inhibitors, providing a new pathway for targeting previously undruggable proteins and addressing the drug resistance problem. PROTACs offer many advantages compared to traditional therapeutics, such as:

1. Wide range of targets, high activity, and the ability to target previously "undruggable" proteins.
2. Improved selectivity, activity, and safety. Can be administered at lower doses due to their catalytic mechanism.
3. Overcoming drug resistance, degrading previously undruggable targets, etc.

However, as a new class of API molecule with large molecular weight and numerous functional groups, it does not comply with Lipinski's Rule of Five (Ro5), resulting in poor drug permeability, solubility, and oral bioavailability.

As a global CDMO serving global innovative pharmaceutical companies and research institutions, Porton has an extensive experience in research and manufacturing services, especially in the field of PROTAC drug development. Porton is committed to the development and production of PROTAC oral formulations and provides customers with comprehensive, reliable, fast, and compliant one-stop services, to meet customers' supply chain needs and facilitating the commercial success of their products from research and development to order fulfillment.

Project Background

An innovative pharmaceutical company has commissioned Porton with formulation development for a new PROTAC drug, aiming to progress the drug development from preclinical research (IND/Phase I) to the critical phase II clinical trials. To seize the market opportunity, the customer expects to complete the IND application within 5 months, and ultimately scale up the production to 40,000 tablets/batch to meet clinical research- and subsequent commercialization needs. The project faces multiple technical challenges:

1. The target PROTAC molecule has a complex structure, high molecular weight, and low solubility and permeability, which significantly restricts the bioavailability and effectiveness of the drug.
2. The tight timeline presents additional challenges for research and development, and IND filing preparation.

In order to address the technical challenges in a timely manner, the Porton team has developed a multiple-approach development strategy, simultaneously exploring various technologies such as nanoparticle delivery, lipid formulations, solid dispersions, etc. Based on the screening results, promising approaches will be selected to ensure the project meets milestones on time, laying a solid foundation for future clinical research and commercialization for the client.

2 A CUSTOMER CENTRIC, INNOVATIVE, AND RELIABLE CDMO WITH GLOBAL SOLUTIONS

Free to Download

Services & Solutions

Porton Selected as a Representative Company in Frost & Sullivan's 2025 China Pharmaceutical CDMO Industry Insight Blue Book

2025-06-25

Frost & Sullivan recently released the 2025 China Pharmaceutical CDMO Industry Insight Blue Book, a comprehensive analysis of the evolution and strategic trajectory of China's pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. Rooted in an in-depth examination of market dynamics, technological innovation, and global competitiveness, the report highlights how China's CDMO industry is reshaping the global pharmaceutical value chain through specialized services, operational agility, and cutting-edge capabilities.



Read more

Company Events

Porton Shanghai Fengxian Manufacturing Site Has Passed the EU QP Audit

2025-06-19

Porton Pharma Solutions Ltd. is glad to announce that its Shanghai Fengxian Manufacturing Site has passed the EU Qualified Person (QP) audit.

The GMP Compliance Statement declares that the quality system and facility of Shanghai Fengxian Manufacturing Site are in compliance with the standard of EU GMP Guidelines EudraLex Volume 4, EU Clinical Trial Regulation, GMP for IMP and ICH Q7.

Read more

Porton Shanghai Pudong R&D and Manufacturing Site Has Passed the EU QP Audit

2025-06-20

Porton Pharma Solutions Ltd. is glad to announce that its Shanghai Pudong R&D and Manufacturing Site has passed the EU Qualified Person (QP) audit.

The GMP Compliance Statement declares that the quality system and facility of Shanghai Pudong R&D and Manufacturing Site are in compliance with the standard of EU GMP Guidelines EudraLex Volume 4, EU Clinical Trial Regulation, GMP for IMP and ICH Q7/Q9/Q10, laying a strong foundation for Porton to further expand its global new molecular business.

Read more

Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa

2025-07-1

Porton Advanced Solutions, a global leader in Advanced Therapy Medicinal Products CDMO Services, and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, have announced the signing of a Memorandum of Understanding (MOU). This agreement will see the two organizations collaborate to establish and strengthen CAR T-cell therapy development and manufacturing capabilities at EVA Pharma's facilities.

Read more

ESG

Porton Awarded Gold Medal by EcoVadis, Ranked Among the Top 5% Globally

2025-06-13

Porton Pharma Solutions Ltd. (Porton) today announced that its Changshou site, a flagship facility for small molecule API manufacturing, has been awarded a gold medal in the latest EcoVadis sustainability rating, placing it among the top 5% of all participating companies globally. This achievement not only reflects Porton’s strong commitment to sustainable development, but also highlights its responsibility in advancing ESG standards across the global pharmaceutical chain.

Read more

Marketing Activities

Previous Events

BOS Basel 2025
June 11-12
Basel, Switzerland

EWOC: Empowering Women in Organic Chemistry
June 12-13
Chicago, Illinois, United States

A Seminar on Development and Regulatory Strategies for Advanced Therapy Medicinal Products
June 19
Beijing, China

The 28th ACS Annual Green Chemistry & Engineering Conference
June 23-26
Pittsburgh, PA, United States

Chemspec Europe
June 4-5
Koelnmesse, Germany

Exploring Therapeutic Frontiers Lunch & Learn
June 12
AC Hotel San Francisco, United States

BIO International Convention 2025
June 16-19
Boston, MA, United States

The 7th David Grant Symposium
June 18-20
Minneapolis, Minnesota, United States

CPHI & PMEC China
June 24-26
Shanghai, China






Upcoming Events

Stay Updated on the Latest Developments, Click to Schedule Your Appointment

Events	Date	Venue	Booth
Interphex Week Tokyo 2025	July 9-11	Tokyo, Japan	E13–29
2025 Antibody ADC XDC Next Generation Coupling Drug Innovation Summit	July 18	Hangzhou, China	A07
2025 Organic Reactions and Processes Gordon Research Conference	July 20-25	Bryant University, Smithfield, RI, United States	\
BIONNOVA West China Forum 2025	July 22-23	Chengdu, China	TBD
BIO Asia-Taiwan 2025	July 23-27	Taiwan, China	M727

Customized Development and Manufacturing

Technical Solutions for Conventional and New Drug Modalities

OEB 1 to 5 | Sub-g to Metric-ton Scale | Pre-clinical to Commercial

- Small Molecules
- Tides
- Biologics and Conjugates
- Advanced Therapy Medicinal Products

Operational Excellence	IP · QA · EHS · RA · PM · Supply Chain
Global Site Compliance	U.S. FOOD & DRUG ADMINISTRATION · World Health Organization · EUROPEAN MEDICINES AGENCY SCIENCE · MEDICINES · HEALTH · PMDA · 国家药品监督管理局 National Medical Products Administration

PORTON

A Customer Centric, Innovative, and Reliable CDMO with Global Solutions

Please contact us to help you on your next development project and achieve your business goals.

LinkedIn
Porton Pharma Solutions

business@portonpharma.com
www.portonpharma.com

Contact Us